Pregled bibliografske jedinice broj: 250706
Quetiapine augmentation in treatment-resistant depression : a naturalistic study
Quetiapine augmentation in treatment-resistant depression : a naturalistic study // Psychopharmacology, 187 (2006), 4; 511-514 doi:10.1007/s00213-006-0452-x (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 250706 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Quetiapine augmentation in treatment-resistant depression : a naturalistic study
Autori
Šagud, Marina ; Mihaljević-Peleš, Alma ; Muck-Šeler, Dorotea ; Jakovljević, Miro ; Pivac, Nela
Izvornik
Psychopharmacology (0033-3158) 187
(2006), 4;
511-514
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
treatment resistant depression; quetiapine; add-on therapy
Sažetak
Rationale Treatment resistant depression (TRD) is a common clinical problem, often complicated with suicidal ideations and greater lifetime functional impairment, and represents a considerable challenge to management and treatment. Objective The aim of a prospective, open-label, non-comparative, flexible-dosed 20-week study was to evaluate the effects of quetiapine, as an add-on therapy, in patients with TRD who were refractory to previous treatments. Method Eighteen patients with major depressive disorder (DSM-IV criteria) were treated for 20 weeks with quetiapine (mean dose 315 ± ; ; ; 109 mg/day). Patients were evaluated at baseline, weekly from 1-9 week, and than after 12, 16 and 20 weeks of treatment, using Hamilton Rating Scale for Depression-17 items (HAMD) scale. Results Fourteen patients with TRD completed the 20-week open trial with quetiapine. The augmentation with quetiapine significantly reduced total scores and scores listed in the anxiety subscale on the HAMD, and these effects were observed after the fourth week of treatment, while the depressed mood scores were significantly reduced after fifth week of treatment. Quetiapine add-on treatment significantly decreased the scores listed in the insomnia subscale on the HAMD subscale after second week of treatment. Conclusions Our preliminary data indicate that quetiapine add-on therapy appears to have beneficial effects in the treatment of patients with TRD.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Institut "Ruđer Bošković", Zagreb,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Rijeka
Profili:
Alma Mihaljević-Peleš
(autor)
Dorotea Muck-Šeler
(autor)
Marina Šagud
(autor)
Nela Pivac
(autor)
Miro Jakovljević
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- MEDLINE